MétaCan
Menu
Back to cohort
Record W4404983178 · doi:10.3389/fphar.2024.1531166

Editorial: Cytochromes P450, their modulators and metabolites in cardiovascular function and disease

2024· editorial· en· W4404983178 on OpenAlexaff
Adeniyi Michael Adebesin, R. J. Roman, William B. Campbell, John M. Seubert, Rheem A. Totah

Bibliographic record

VenueFrontiers in Pharmacology · 2024
Typeeditorial
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicEicosanoids and Hypertension Pharmacology
Canadian institutionsUniversity of Alberta
FundersNational Heart, Lung, and Blood InstituteNational Institute on Aging
KeywordsEpoxide hydrolase 2EpoxygenaseEpoxyeicosatrienoic acidPharmacologyDocosahexaenoic acidChemistryArachidonic acidIberiotoxinVasodilationCytochrome P450BiochemistryInternal medicineEndocrinologyMedicineEnzymePolyunsaturated fatty acidFatty acid

Abstract

fetched live from OpenAlex

The review by Jiang et al. discusses the cardioprotective mechanisms of epoxyeicosatrienoic acids (EETs), epoxyeicosatetraenoic acids (EEQs), and epoxydocosapentaenoic acids (EDPs), which are CYP epoxygenase metabolites of arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), respectively. Research from various laboratories suggests that these metabolites are endothelium-derived hyperpolarization factors (EDHF) involved in blood vessel vasodilation and renal tubular salt reabsorption via actions on potassium, calcium, and sodium channels. Their proposed mechanisms of action include direct binding to ion channels and indirect modulation of ion channels via G-protein and protein kinase pathways. Therefore, EET mimetics and soluble epoxide hydrolase (sEH) inhibitors, which block epoxide hydrolysis of endogenous EETs, show significant blood pressure lowering effects in various hypertensive animal models. Other notable protective effects of EETs in CVD models include: 1) pro-angiogenesis and anti-apoptosis in myocardial infarction (MI) models, 2) antiinflammation in atherosclerosis models, and 3) anti-oxidant effects and modulation of calcium homeostasis in heart failure models. The review also covers non-hydrolase functions of sEH in CVD, an often overlooked activity, as well as cell type-specific mechanisms of EETs and sEH inhibitors.In the article by Baranowska et al., the combination of low-dose (10mg/kg/day) of an orally-active, stable EET mimetic (EET-A) and a low dose (10mg/kg/day) of AAA, a 20-hydroxyeicosatetraenoic acid (20-HETE) antagonist, was shown to provide superior blood pressure lowering effect than a higher dose (40 mg/kg/day) of EET-A alone in a spontaneously hypertensive rat model. 20-HETE is produced by the metabolism of arachidonic acid by the CYP4A and F subfamilies and is a vasoconstrictor in various vascular beds that contributes to the development of hypertension in SHR. These results indicate a prominent role for the 20-HETE/CYP4 pathway in the vascular dysfunction in this model and suggest a promising therapeutic strategy for the treatment of hypertension, which warrants additional investigation.Helal et al. assessed the effects of individual (R/S)-enantiomers of 11-hydroxyeicosatetraenoic acid (11-HETE) on CYP1B1 activity and cellular hypertrophy in RL-14 cardiomyocyte cells. 11-HETE is an arachidonic acid metabolite produced by CYPs, cyclooxygenase (COX 1/2) enzymes, and non-enzymatic oxidative processes. Both enantiomers increased cardiomyocyte hypertrophy but only the 11(S)enantiomer increased CYP1B1 activity. Interestingly, the 11-(S)-enantiomer increased the mRNA and protein expression of both cardioprotective CYP2J and pro-inflammatory 20-HETE producing CYP4F2, while the 11(R)-enantiomer did not increase CYP2J levels. These results are consistent with previous work by the El-Kadi group on the differential effects of HETE enantiomers on CYP expression and activity that suggest the existence of distinct binding sites/receptors for each enantiomer. Other potential implications include: 1) a positive fed-back loop in the 11-HETE/CYP1B1 axis could exacerbate cardiac hypertrophy, 2) secondary metabolism of eicosanoids by 11-HETE induced CYPs might be relevant in cardiac hypertrophy, and 3) CYP expression and activity may encompass an equilibrium between antiand pro-inflammatory eicosanoids, which potentially become skewed during oxidative stress or in diseased states. Strategies to restore the normal equilibrium between these isoforms might provide safer, more effective treatments for CVD.Finally, using a multidisciplinary approach, Chu et al. elucidated the antihypertensive mechanism of action of tetrandrine, a bioactive alkaloid component of Stephania tetrandra S Moore root (Fang Ji), a traditional Chinese medicine used for decades for its diuretic and antihypertensive actions. They also demonstrated that chronic administration of tetrandrine (30 and 60 mg/Kg/day) to SHR was as effective as spironolactone (20 mg/Kg/day) in increasing sodium excretion and lowering blood pressure in spontaneously hypertensive rats. This work identifies tetrandrine as a diuretic that covalently binds to CYP11A1 in an unconventional way to inhibit aldosterone biosynthesis. The proposed mechanism should help researchers/clinicians understand its pharmacological effects and to explore future therapeutic applications, particularly for heart failure. Future work should investigate the inhibition of other CYPs by tetrandrine.In summary, the articles in this RT contribute to our understanding of the roles of CYPs, their metabolites and modulators in CVD. The discoveries from these outstanding laboratories contained in this RT will stimulate further research on these topics and spawn additional innovative ideas and therapies to improve cardiovascular health.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.007
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Editorial · Consensus signal: Editorial
Teacher disagreement score0.022
Threshold uncertainty score0.075

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.007
Meta-epidemiology (narrow)0.0040.001
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0030.001
Science and technology studies0.0010.002
Scholarly communication0.0040.003
Open science0.0030.001
Research integrity0.0080.009
Insufficient payload (model declined to judge)0.0220.014

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.004
GPT teacher head0.241
Teacher spread0.236 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEditorial

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueFrontiers in PharmacologySame topicEicosanoids and Hypertension PharmacologyFrench-language works237,207